While GSK already publicly discloses information of almost 5,000 clinical trials on one of its websites, the company is now committing to make clinical study reports (CSRs) for all of its medicines publicly available through its clinical trials register. CSRs provide details on the design, methods and results of clinical trials.
GSK has also indicated its intention to publish CSRs for previously approved medicines. While this is a large project anticipated to take years, priority will be given to its most commonly prescribed medicines.
Patrick Vallance, president of pharmaceuticals research and development at GSK, said: ‘All those involved in the conduct and publication of clinical research, whether healthcare companies like GSK, academia or research organisations, have a role to play in ensuring that the data they generate are made publicly available to help bring patient benefit.’
Welcoming the move, Jenny Freeman, RSS vice president of external affairs and senior lecturer in medical statistics at the University of Sheffield, said: ‘The RSS is keen to promote transparency in all areas which involve statistics and its uses, whether this be clinical trials or elsewhere. It is only possible to make informed decisions when all the relevant data are available.’